Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
July 2016

Recent Stories

From Specialty Pharmacy News - Conventional thinking has been that women with breast cancer who undergo radiation do so for a five-to-seven-week period. But studies have shown that a shorter course of three to four weeks can be just as effective, as well as better in some ways, including cosmetic outcomes, cost of treatment and patient convenience. Many providers, however, are not offering the shorter regimen when it would be appropriate. Read more

With the FDA approval of another sofosbuvir-based medication, Gilead Sciences, Inc. continues… Read more

Although CMS has yet to make an announcement, a spokesperson for the… Read more

Blue Cross and Blue Shield of New Mexico earlier this year launched… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

July 11, 2016
FDA Approves First Monthly Injection for PCSK9

Amgen’s PCSK9 inhibitor Repatha gets FDA approval for injector with once-monthly dosing, making it first PCSK9 with this option. New Pushtronex system with prefilled cartridge will be available in August

June 28, 2016
FDA OKs Another Gilead Hep C Therapy

The FDA approved the new Gilead drug Epclusa, the first product indicated to treat all six main genotypes of hepatitis C. Cost for 12 weeks reportedly is $74,000

June 7, 2016
Genentech, OSI Settle False Claims Allegations for $67M

Genentech and OSI Pharmaceuticals will pay $67 million to settle false claims allegations on statements the companies made about cancer drug Tarceva.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?